Phosphorylation of β-arrestin 2 at Thr383 by MEK underlies β-arrestin-dependent activation of Erk1/2 by GPCRs
- CNRS, UMR-5203, Institut de Génomique Fonctionnelle, France
- INRA, UMR85, Unité Physiologie de la Reproduction et des Comportements, France
Abstract
In addition to their role in desensitization and internalization of G protein-coupled receptors (GPCRs), β-arrestins are essential scaffolds linking GPCRs to Erk1/2 signaling. However, their role in GPCR-operated Erk1/2 activation differs between GPCRs and the underlying mechanism remains poorly characterized. Here, we show that activation of serotonin 5-HT2C receptors, which engage Erk1/2 pathway via a β-arrestin-dependent mechanism, promotes MEK-dependent β-arrestin 2 phosphorylation at Thr383, a necessary step for Erk recruitment to the receptor/β-arrestin complex and Erk activation. Likewise, Thr383 phosphorylation is involved in β-arrestin-dependent Erk1/2 stimulation elicited by other GPCRs such as β2-adrenergic, FSH and CXCR4 receptors, but does not affect the β-arrestin-independent Erk1/2 activation by 5-HT4 receptor. Collectively, these data show that β-arrestin 2 phosphorylation at Thr383 underlies β-arrestin-dependent Erk1/2 activation by GPCRs.
Article and author information
Author details
Funding
Fondation pour la Recherche Médicale (Contract Equipe FRM 2009)
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Agence Nationale de la Recherche (Contract ANR-2011-1619 01)
- Elisabeth Cassier
- Nathalie Gallay
- Thomas Bourquard
- Sylvie Claeysen
- Joël Bockaert
- Pascale Crépieux
- Anne Poupon
- Eric Reiter
- Philippe Marin
- Franck Vandermoere
Centre National de la Recherche Scientifique
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Institut National de la Santé et de la Recherche Médicale
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Université de Montpellier
- Elisabeth Cassier
- Sylvie Claeysen
- Joël Bockaert
- Philippe Marin
- Franck Vandermoere
Institut National de la Recherche Agronomique
- Nathalie Gallay
- Thomas Bourquard
- Pascale Crépieux
- Anne Poupon
- Eric Reiter
Université François-Rabelais
- Nathalie Gallay
- Thomas Bourquard
- Pascale Crépieux
- Anne Poupon
- Eric Reiter
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2017, Cassier et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,717
- views
-
- 598
- downloads
-
- 54
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Phosphorylation of β-arrestin 2 at Thr383 by MEK underlies β-arrestin-dependent activation of Erk1/2 by GPCRs
eLife 6:e23777.
https://doi.org/10.7554/eLife.23777
Further reading
-
- Cell Biology
- Chromosomes and Gene Expression
Meiotic crossover recombination is essential for both accurate chromosome segregation and the generation of new haplotypes for natural selection to act upon. This requirement is known as crossover assurance and is one example of crossover control. While the conserved role of the ATPase, PCH-2, during meiotic prophase has been enigmatic, a universal phenotype when pch-2 or its orthologs are mutated is a change in the number and distribution of meiotic crossovers. Here, we show that PCH-2 controls the number and distribution of crossovers by antagonizing their formation. This antagonism produces different effects at different stages of meiotic prophase: early in meiotic prophase, PCH-2 prevents double-strand breaks from becoming crossover-eligible intermediates, limiting crossover formation at sites of initial double-strand break formation and homolog interactions. Later in meiotic prophase, PCH-2 winnows the number of crossover-eligible intermediates, contributing to the designation of crossovers and ultimately, crossover assurance. We also demonstrate that PCH-2 accomplishes this regulation through the meiotic HORMAD, HIM-3. Our data strongly support a model in which PCH-2’s conserved role is to remodel meiotic HORMADs throughout meiotic prophase to destabilize crossover-eligible precursors and coordinate meiotic recombination with synapsis, ensuring the progressive implementation of meiotic recombination and explaining its function in the pachytene checkpoint and crossover control.
-
- Cell Biology
- Physics of Living Systems
Cell mechanical properties determine many physiological functions, such as cell fate specification, migration, or circulation through vasculature. Identifying factors that govern the mechanical properties is therefore a subject of great interest. Here, we present a mechanomics approach for establishing links between single-cell mechanical phenotype changes and the genes involved in driving them. We combine mechanical characterization of cells across a variety of mouse and human systems with machine learning-based discriminative network analysis of associated transcriptomic profiles to infer a conserved network module of five genes with putative roles in cell mechanics regulation. We validate in silico that the identified gene markers are universal, trustworthy, and specific to the mechanical phenotype across the studied mouse and human systems, and demonstrate experimentally that a selected target, CAV1, changes the mechanical phenotype of cells accordingly when silenced or overexpressed. Our data-driven approach paves the way toward engineering cell mechanical properties on demand to explore their impact on physiological and pathological cell functions.
